Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HIV-1 RT inhibitor
Trovirdine inhibits HIV-1 RT with an IC50 of 7 nM when employing heteropolymeric primer/template (oligo-DNA/ribosomal RNA)and dGTP as substrate. -
HIV Entry Inhibitor
BMS-806, also known as BMS-378806 , is a type of medicine called an entry inhibitor. Entry inhibitors work by blocking HIV from entering human cells. BMS-378806 (BMS-806) is a small molecule that blocks the binding of host-cell CD4 with viral gp120 protein and therefore inhibits the first steps of HIV-1 infection. -
HIV-1 integrase inhibitor
HIV-1 integrase inhibitor is uesful for anti-HIV. -
HIV-1 integrase inhibitor
HIV-1 integrase inhibitor 2, in the treatment of human immunodeficiency virus (HIV) infection. -
HIV Protease Inhibitor
Saquinavir mesylate is an HIV Protease Inhibitor used in antiretroviral therapy. -
HIV protease inhibitor
Darunavir Ethanolate (Prezista) is an HIV protease inhibitor. -
HIV Integrase Inhibitor
GSK1265744 (GSK744) is a potential inhibitor of HIV integrase with IC50 value of 3 nM -
HIV-1 attachment inhibitor
BMS-626529 is a potent HIV-1 attachment inhibitor. BMS-663068 is also the phosphonooxymethyl prodrug of BMS-626529 that targets HIV-1 gp120 and prevents its binding to CD4(+) T cells. -
HIV protease inhibitor
Nelfinavir Mesylate is a potent HIV protease inhibitor with Ki of 2 nM. -
HIV-1 maturation inhibitor
GSK3532795, also known as BMS-955176, is a potent, orally active, second-generation HIV-1 maturation inhibitor. CAS: 1392312-45-6 (free base) 2023808-13-9 (HCl) 2023798-97-0 (HCl hydrate) 2097784-79-5 (oxalate) -
HIV-1 nucleotide reverse transcriptase inhibitor
Tenofovir alafenamide fumarate (GS-7340 fumarate) is an investigational oral prodrug of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor. -
HIV-1 nucleotide reverse transcriptase inhibitor
Tenofovir alafenamide hemifumarate (GS-7340 hemifumarate) is an investigational oral prodrug of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor. -
HIV fusion inhibitor
Enfuvirtide Acetate (T-20) is a 36 amino acid peptide corresponding to a region of gp41, the transmembrane subunit of HIV-1 envelope protein. -
HIV maturation inhibitor
GSK2838232-isomer is a novel human immune virus (HIV) maturation inhibitor being developed for the treatment of chronic HIV infection.
-
HIV integrase inhibitor
GSK744 is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection. -
HIV integrase inhibitor
Dolutegravir sodium is a HIV integrase inhibitor(IC50= 2.7 nM), modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H. -
HIV-1 capsid CTD dimerization inhibitor
Ebselen (SPI-1005) is an inhibitor of HIV-1 capsid CTD dimerization. Ebselen can permeate the blood-brain barrier and inhibit inositol monophosphatase (IMPase). Ebselen is a non-toxic seleno-organic drug with anti-inflammatory and antioxidant properties. Ebselen inhibits QSOX1 enzymatic activity and has anticancer activity . -
HIV-1 reverse transcriptase inhibitor
beta-L-D4A is a nucleoside HIV-1 reverse transcriptase inhibitor. -
HIV capsid inhibitor
CA inhibitor 1 (GS-6207 analog) is a potent HIV capsid inhibitor for HIV inhibition. -
HIV infection inhibitor
HIV-1 inhibitor-3 is a HIV infection inhibitor extracted from patent US2018360927. -
HIV-1 attachment inhibitor
BMS-663068 tris is an HIV-1 attachment inhibitor in development for the treatment of HIV-1 infection. -
HIV protease inhibitor
Fosamprenavir Calcium Salt is a phosphate ester prodrug of the antiretroviral protease inhibitor amprenavir, with improved solubility over the parent molecule and a potential for reduced pill burden on current dosing regimens; GW433908G is the calcium salt of the prodrug. -
HIV protease inhibitor
Tipranavir, a nonpeptidic HIV protease inhibitor (NPPI), inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-PI-resistant HIV-1 isolates. -
HIV Protease Inhibitor
Indinavir is a selective inhibitor of HIV-1 protease, displaying a Ki value of 0.54 nM, making it a potent antiviral agent. In addition to its primary role in HIV treatment, Indinavir has demonstrated anticancer properties by inhibiting matrix metalloproteinases (MMPs) and promoting anti-angiogenic effects, alongside inducing apoptosis in cancer cells. Furthermore, Indinavir has shown inhibitory activity against the SARS-CoV 3CL protease, expanding its potential applications in viral research. -
HIV Integrase Inhibitor
Equisetin is an N-methylserine-derived acyl tetramic acid that functions as a potent HIV integrase inhibitor. It specifically interferes with the activity of HIV-1 integrase and demonstrates notable inhibition of 11β-HSD1 and Dnp-stimulated ATPase, with an IC50 of approximately 8 nmol per mg of protein. Additionally, Equisetin exhibits significant antibacterial properties, anti-inflammatory effects, and potential benefits in managing lipid-associated disorders while also showcasing cytotoxic activity. This compound is valuable for research applications focused on HIV treatment and the exploration of antimicrobial and anti-inflammatory mechanisms. -
HIV Protease Inhibitor
Indinavir sulfate ethanolate is a selective inhibitor of HIV-1 protease, demonstrating a potent Ki of 0.54 nM for the target enzyme. Beyond its antiviral activity, this compound has shown potential in anticancer research through the inhibition of MMPs-2 activation, anti-angiogenic effects, and promotion of apoptosis. Additionally, Indinavir sulfate ethanolate acts as an inhibitor of the SARS-CoV 3CLpro enzyme, highlighting its diverse biological activity and relevance in multiple research applications. -
HIV-1 RT Inhibitor
Apricitabine is a selective inhibitor of HIV-1 reverse transcriptase (RT) with a Ki value of 0.08 μM. It also exerts inhibitory effects on DNA polymerases α, β, and γ, with corresponding Ki values of 300 μM, 12 μM, and 112.25 μM. Demonstrating significant antiretroviral efficacy and favorable tolerability, Apricitabine shows a reduced potential for resistance development in patients with antiretroviral-naive HIV infection. This compound is applicable for research in the mechanisms of HIV-1 replication and antiviral drug development. -
DNA Synthesis/HSV/HIV-1 Inhibitor
16,16-Dimethyl prostaglandin A1 is a prostaglandin analog that primarily inhibits DNA synthesis. It demonstrates significant antiviral activity by reducing viral replication in both herpes simplex virus (HSV) and HIV-1 infection models. This compound serves as a valuable tool for research focused on cancer biology and viral pathogenesis. -
HIV-1 Reverse Transcriptase Inhibitor
R82913 (9-Cl-TIBO) is a selective inhibitor of HIV-1 reverse transcriptase, demonstrating significant antiviral activity against both RNA and DNA templates crucial for viral replication. This compound effectively inhibits the replication of various HIV-1 strains in CEM cells, with a median IC50 value of 0.15 μM. It serves as a valuable reagent for research applications focused on HIV therapy development and reverse transcriptase inhibition studies. -
HIV Inhibitor
Fozivudine tidoxil is an orally active HIV inhibitor designed as a thioether lipid-zidovudine (ZDV) conjugate. This compound exhibits potent anti-HIV activity by incorporating into the newly synthesized DNA strand during viral replication, leading to irreversible binding to viral reverse transcriptase and disruption of the reverse transcription process. In addition to its antiviral properties, Fozivudine tidoxil is also a versatile click chemistry reagent, capable of undergoing copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with suitable alkyne or DBCO/BCN-containing molecules, making it valuable for chemical biology applications. -
HIV-1 Inhibitor
HIV-1 Inhibitor-43 is a selective inhibitor targeting the HIV-1 virus. It demonstrates potent efficacy with an EC50 of 21.3 nM for Y188L mutants, 6.2 nM for K103N-Y181C, and under 0.7 nM for both K103N and Y181C strains. This compound effectively reduces HIV-1 RNA levels and protein p24 expression, making it a valuable tool for research in HIV pathogenesis and therapeutic development. -
DENV/HIV-1 Inhibitor
DENV-IN-5 is a potent inhibitor targeting both dengue virus (DENV) and HIV-1 replication. It demonstrates effective antiviral activity with half-maximal effective concentration (EC50) values of 1.47, 9.23, 7.08, and 8.91 μM against DENV serotypes I to IV, respectively. Additionally, DENV-IN-5 inhibits the HIV-1 IIIB strain with an EC50 of 0.1512 μM. This compound is valuable for research focused on viral infections and the development of antiviral therapies. -
HIV/HBV Inhibitor
L-2'-Fd4C is an L-nucleoside analogue that acts as an inhibitor of both human immunodeficiency virus (HIV) and hepatitis B virus (HBV). This compound exhibits potent antiviral activity, making it valuable for research focused on the treatment and understanding of these viral infections. Its unique mechanism of action may provide insights into the development of novel therapeutic strategies against HIV and HBV. -
HIV-1 Inhibitor
SJP-L-5 is an HIV-1 capsid dissociation inhibitor that targets the HIV-1 viral capsid, preventing its normal function. It demonstrates significant inhibitory activity against various HIV-1 strains, with an EC50 ranging from 0.16 to 0.97 μg/mL. By effectively blocking the entry of HIV-1 viral DNA into the nucleus, SJP-L-5 offers valuable potential for applications in HIV-1 infection research and development of antiviral therapies. -
HIV-Ⅰ Inhibitor
HIV-IN-6 is an inhibitor of HIV-1 viral replication, specifically targeting Src family kinases (SFKs) that associate with the viral Nef protein, including Hck. This compound has demonstrated significant antiviral activity by disrupting the functional interactions necessary for viral pathogenesis. Its application in research includes the study of HIV infection mechanisms and the exploration of novel therapeutic strategies against HIV-1. -
HIV-1 Integrase Inhibitor
GSK-1264 is an HIV-1 integrase inhibitor that targets the catalytic core and C-terminal domains of the HIV-1 integrase enzyme. By promoting the formation of an open polymer structure of integrase dimers, GSK-1264 disrupts the late stages of HIV replication and interferes with viral particle assembly. This compound is valuable for research focused on HIV infection and understanding integrase-mediated processes in the viral life cycle. -
HIV-1 Integrase Inhibitor
HIV-1 Integrase Inhibitor 8 is a selective inhibitor targeting the HIV-1 integrase enzyme. It demonstrates potent activity against viral replication by disrupting the integration of viral DNA into the host genome, which is essential for the HIV life cycle. This compound is primarily utilized in research focused on antiretroviral therapy and the development of HIV treatments, contributing to the understanding of integrase inhibition mechanisms. -
HIV-1Integrase Inhibitor
GSK3839919A is a potent allosteric inhibitor of HIV-1 integrase, targeting the enzyme responsible for the integration of viral DNA into the host genome. This compound exhibits significant antiviral activity against HIV-1, making it a valuable tool for research applications focused on the development of novel antiretroviral therapies and the study of HIV replication mechanisms. Its unique mechanism of action may provide insights into resistance pathways and inform drug design strategies. -
HIV Integrase Inhibitor
His-Cys-Lys-Phe-Trp-Trp is an HIV integrase inhibitor, exhibiting an IC50 of 2 μM. This compound impedes the integrase enzyme's function, thereby preventing viral DNA integration into the host genome. His-Cys-Lys-Phe-Trp-Trp is valuable for research focused on HIV pathogenesis and the development of antiretroviral therapies. -
HIV-1 integrase Inhibitor
(S)-BI-1001 is a potent HIV-1 integrase inhibitor, demonstrating significant antiviral activity. It exhibits an IC50 value of 28 nM, an EC50 of 450 nM, and a Kd of 4.7 μM, indicating its efficacy in disrupting viral replication processes. This compound is valuable for research applications focused on HIV-1 pathogenesis and therapeutic development. -
HIV-1 Integrase Inhibitor
HIV-1 Integrase Inhibitor 7 is a potent inhibitor of HIV-1 integrase, exhibiting an IC50 value of 33.3 nM. This compound effectively interferes with the integration of viral DNA into the host genome, making it essential for studies focused on HIV-1 replication and treatment strategies. It serves as a valuable tool in research applications aimed at understanding HIV-1 biology and developing therapeutic interventions against HIV.
